| Variable . | TIL ≥ 40 (37) . | TIL < 40 (100) . | P-value . |
|---|---|---|---|
| Age (median) | 49.5 (33-67) | 51 (28-81) | .84 |
| Postmenopausal (%) | 17 (47.2) | 52 (52) | .70 |
| Family history (%) | 5 (13.9) | 13 (13) | .77 |
| ECOG PS 0 (%) | 33 (91.7) | 86 (86) | .11 |
| HR positive (%) | 21 (58.3) | 64 (64) | .93 |
| HER2 3+ (%) | 32 (88.9) | 83 (83) | .59 |
| Mean initial Ki67 | 48.1 | 42 | NA |
| Median initial Ki67 (range) | 45 (25-90) | 40 (10-90) | .07 |
| Tumor grade 3 | 25 (69.4) | 43 (43) | .01 |
| Tumor size (mean) | 2.85 | 3.12 | .88 |
| Clinical node positivity (%) | 32 (88.9) | 84 (84) | .98 |
| Neoadjuvant T + TP (%) | 19 (52.8) | 44 (44) | .43 |
| Variable . | TIL ≥ 40 (37) . | TIL < 40 (100) . | P-value . |
|---|---|---|---|
| Age (median) | 49.5 (33-67) | 51 (28-81) | .84 |
| Postmenopausal (%) | 17 (47.2) | 52 (52) | .70 |
| Family history (%) | 5 (13.9) | 13 (13) | .77 |
| ECOG PS 0 (%) | 33 (91.7) | 86 (86) | .11 |
| HR positive (%) | 21 (58.3) | 64 (64) | .93 |
| HER2 3+ (%) | 32 (88.9) | 83 (83) | .59 |
| Mean initial Ki67 | 48.1 | 42 | NA |
| Median initial Ki67 (range) | 45 (25-90) | 40 (10-90) | .07 |
| Tumor grade 3 | 25 (69.4) | 43 (43) | .01 |
| Tumor size (mean) | 2.85 | 3.12 | .88 |
| Clinical node positivity (%) | 32 (88.9) | 84 (84) | .98 |
| Neoadjuvant T + TP (%) | 19 (52.8) | 44 (44) | .43 |
Abbreviations: ECOG PS, eastern cooperative oncology group performance score; HR, hormone receptor; pCR, pathological complete response; T + TP, taxane plus trastuzumab-pertuzumab; TILs, tumor-infiltrating lymphocyte.
| Variable . | TIL ≥ 40 (37) . | TIL < 40 (100) . | P-value . |
|---|---|---|---|
| Age (median) | 49.5 (33-67) | 51 (28-81) | .84 |
| Postmenopausal (%) | 17 (47.2) | 52 (52) | .70 |
| Family history (%) | 5 (13.9) | 13 (13) | .77 |
| ECOG PS 0 (%) | 33 (91.7) | 86 (86) | .11 |
| HR positive (%) | 21 (58.3) | 64 (64) | .93 |
| HER2 3+ (%) | 32 (88.9) | 83 (83) | .59 |
| Mean initial Ki67 | 48.1 | 42 | NA |
| Median initial Ki67 (range) | 45 (25-90) | 40 (10-90) | .07 |
| Tumor grade 3 | 25 (69.4) | 43 (43) | .01 |
| Tumor size (mean) | 2.85 | 3.12 | .88 |
| Clinical node positivity (%) | 32 (88.9) | 84 (84) | .98 |
| Neoadjuvant T + TP (%) | 19 (52.8) | 44 (44) | .43 |
| Variable . | TIL ≥ 40 (37) . | TIL < 40 (100) . | P-value . |
|---|---|---|---|
| Age (median) | 49.5 (33-67) | 51 (28-81) | .84 |
| Postmenopausal (%) | 17 (47.2) | 52 (52) | .70 |
| Family history (%) | 5 (13.9) | 13 (13) | .77 |
| ECOG PS 0 (%) | 33 (91.7) | 86 (86) | .11 |
| HR positive (%) | 21 (58.3) | 64 (64) | .93 |
| HER2 3+ (%) | 32 (88.9) | 83 (83) | .59 |
| Mean initial Ki67 | 48.1 | 42 | NA |
| Median initial Ki67 (range) | 45 (25-90) | 40 (10-90) | .07 |
| Tumor grade 3 | 25 (69.4) | 43 (43) | .01 |
| Tumor size (mean) | 2.85 | 3.12 | .88 |
| Clinical node positivity (%) | 32 (88.9) | 84 (84) | .98 |
| Neoadjuvant T + TP (%) | 19 (52.8) | 44 (44) | .43 |
Abbreviations: ECOG PS, eastern cooperative oncology group performance score; HR, hormone receptor; pCR, pathological complete response; T + TP, taxane plus trastuzumab-pertuzumab; TILs, tumor-infiltrating lymphocyte.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
